TIDMIMM

RNS Number : 0005A

Immupharma PLC

21 December 2017

 
   21 DECEMBER 2017 
 

ImmuPharma PLC

("ImmuPharma" or the "Company")

Grant of Options

ImmuPharma PLC (LSE:IMM), ("ImmuPharma" or the "Company"), the specialist drug discovery and development company, announces the approval of the grant of options over a total of 900,000 ordinary shares of 10p each in the Company ("Ordinary Shares") to certain of its consultants who have been directly involved in Lupuzor(TM)'s successful development to date, representing 0.679% of ImmuPharma's Ordinary Shares and total voting rights on a fully diluted basis (the "Options"). The Options were granted upon the recommendation of the Company's remuneration committee.

The exercise price for the Options is 153 pence being the closing middle market share price on 20 December 2017. The Options will vest subject to certain conditions after three years and are exercisable between three and ten years from the date of grant.

Total Share Options

The total options outstanding under both the 2017 Plan and the Company's previous share option plan is 10,130,000, representing 7.64% of ImmuPharma's Ordinary Shares and total voting rights on a fully diluted basis. The total options outstanding that have been granted to non-employees and consultants is 6,085,000. The total warrants outstanding is 153,850. Taken altogether, there are currently 16,368,850 outstanding options and warrants, representing 12.35% of ImmuPharma's Ordinary Shares and total voting rights on a fully diluted basis.

This announcement contains inside information for the purpose of Article 7 of Regulation (EU) 596/2014.

Ends

For further information, please contact:

 
 ImmuPharma plc (www.immupharma.co.uk) 
---------------------------------------  --------------------- 
 Tim McCarthy, Chairman 
  Lisa Baderoon, Head of Investor         +44 (0) 20 7152 
  Relations                                4080 
  Twitter: @immupharma                     +44 (0) 7721 413496 
---------------------------------------  --------------------- 
 Northland Capital Partners Limited 
  (NOMAD & Broker) 
  Patrick Claridge, Corporate 
  Finance 
  David Hignell, Corporate Finance 
  Jamie Spotswood, Corporate Finance      +44 (0) 20 3861 
  Rob Rees, Corporate Broking              6625 
---------------------------------------  --------------------- 
 

This information is provided by RNS

The company news service from the London Stock Exchange

END

MSCTMBPTMBJTBAR

(END) Dow Jones Newswires

December 21, 2017 02:05 ET (07:05 GMT)

Immupharma (LSE:IMM)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more Immupharma Charts.
Immupharma (LSE:IMM)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more Immupharma Charts.